Algernon Pharmaceuticals Inc.
AGN
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -42.15% | -58.31% | -54.47% | -49.67% | -38.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.36% | -54.49% | -54.39% | -42.16% | -44.67% |
| Operating Income | 42.36% | 54.49% | 54.39% | 42.16% | 44.67% |
| Income Before Tax | 93.25% | 92.52% | 59.65% | 17.41% | 22.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 93.25% | 92.52% | 59.65% | 17.41% | 22.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 93.25% | 92.52% | 59.65% | 17.41% | 22.26% |
| EBIT | 42.36% | 54.49% | 54.39% | 42.16% | 44.67% |
| EBITDA | 42.30% | 54.56% | 54.45% | 42.31% | 44.98% |
| EPS Basic | 94.72% | 92.71% | 85.76% | 64.20% | 62.06% |
| Normalized Basic EPS | 66.69% | 74.50% | 92.79% | 70.82% | 67.50% |
| EPS Diluted | 92.95% | 91.51% | 84.81% | 64.11% | 61.98% |
| Normalized Diluted EPS | 66.18% | 74.17% | 92.58% | 70.82% | 67.50% |
| Average Basic Shares Outstanding | 37.18% | 32.34% | 129.62% | 127.90% | 118.23% |
| Average Diluted Shares Outstanding | 37.94% | 33.17% | 130.95% | 127.90% | 118.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |